Treatment of Xerosis Cutis with Purulent Drainage
For xerosis cutis (dry skin) with purulent drainage indicating bacterial infection, first-line treatment should include incision and drainage of the purulent collection followed by antibiotic therapy with an agent active against Staphylococcus aureus, such as dicloxacillin, cephalexin, clindamycin, or trimethoprim-sulfamethoxazole (TMP-SMX), depending on local MRSA prevalence. 1
Initial Assessment and Management
- Purulent drainage from dry skin indicates a bacterial infection that has likely formed an abscess requiring drainage 1
- Incision and drainage is the primary treatment for any purulent collection or abscess 1
- Gram stain and culture of the purulent material should be obtained to guide antibiotic therapy 1
- Systemic signs of infection (fever >38°C, tachycardia >90 beats/min, tachypnea >24 breaths/min, abnormal WBC) indicate need for more aggressive treatment 1
Antibiotic Selection Algorithm
For Mild Infection (no systemic symptoms):
First-line oral options for MSSA (methicillin-susceptible S. aureus):
If MRSA is suspected or confirmed:
For Moderate to Severe Infection (with systemic symptoms):
- Intravenous therapy options:
Special Considerations
- Underlying xerosis management: While treating the infection, address the underlying xerosis with moisturizers containing urea, ceramides, or other humectants 3
- Duration of therapy: 5-10 days of antibiotic therapy is recommended, but can be individualized based on clinical response 1
- For recurrent infections: Consider decolonization with intranasal mupirocin twice daily plus daily chlorhexidine washes for 5 days 1
Monitoring and Follow-up
- Assess response to treatment within 48-72 hours 1
- If no improvement or worsening after initial therapy, consider:
Important Caveats
- Simple abscesses with adequate drainage may not require antibiotics if there are no systemic symptoms or risk factors 1
- Beta-lactam antibiotics alone (like cephalexin) remain first-line for non-purulent cellulitis where streptococci are the likely pathogens 1
- In patients with significant comorbidities (diabetes, immunosuppression), broader coverage and more aggressive treatment may be warranted 1
- Avoid fluoroquinolones for MRSA infections as they have inadequate coverage 1
- TMP-SMX should be avoided in pregnant women in the third trimester and infants younger than 2 months 1